AKT1 and liver cancer: Studies have found that BBR can inhibit the Akt pathway and the S-phase kinase-associated protein 2 (Skp2), promote the expression and translocation of Forkhead box O3a (FoxO3a) to the nucleus, and promote the transcription of the cyclin-dependent kinase inhibitors (CDKIs) p21Cip1 and p27Kip1, resulting in G0/G1 cell cycle arrest in liver cancer cells (Li et al., 2018).